Therapeutic cancer vaccines: Advancements, challenges, and prospects

Fan, Ting; Zhang, Mingna; Yang, Jingxian; Zhu, Zhounan; Cao, Wanlu; Dong, Chunyan

doi:10.1038/s41392-023-01674-3

Cited by 597Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Therapeutic cancer vaccines: Advancements, challenges, and prospects

Open access

Fan, Ting, Zhang, Mingna, Yang, Jingxian, Zhu, Zhounan, Cao, Wanlu, Dong, Chunyan·2023·Signal Transduction and Targeted Therapy

DOI 10.1038/s41392-023-01674-3PMC PMC10716479

Open this paper in CoChat — free account Open PDF

Abstract

With the development and regulatory approval of immune checkpoint inhibitors and adoptive cell therapies, cancer immunotherapy has undergone a profound transformation over the past decades. Recently, therapeutic cancer vaccines have shown promise by eliciting de novo T cell responses targeting tumor antigens, including tumor-associated antigens and tumor-specific antigens. The objective was to amplify and diversify the intrinsic repertoire of tumor-specific T cells. However, the complete realization of these capabilities remains an ongoing pursuit. Therefore, we provide an overview of the current landscape of cancer vaccines in this review. The range of antigen selection, antigen delivery systems development the strategic nuances underlying effective antigen presentation have pioneered cancer vaccine design. Furthermore, this review addresses the current status of clinical trials and discusses their strategies, focusing on tumor-specific immunogenicity and anti-tumor efficacy assessment. However, current clinical attempts toward developing cancer vaccines have not yielded breakthrough clinical outcomes due to significant challenges, including tumor immune microenvironment suppression, optimal candidate identification, immune response evaluation, and vaccine manufacturing acceleration. Therefore, the field is poised to overcome hurdles and improve patient outcomes in the future by acknowledging these clinical complexities and persistently striving to surmount inherent constraints.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41392-023-01674-3

Cites

235 of 235 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Up until now, four main platforms of anti-tumor vaccines have been studied: those utilizing dendritic cells, peptide antigens, viral or bacterial vectors, and those utilizing whole tumor antigens.
“Up until now, Up until now, four main platforms of anti-tumor vaccines have been studied: those utilizing dendritic cells (DCs), peptide antigens, viral or bacterial vectors and those utilizing ehole tumor antigens [145].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [145]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1× · see citing works
“206 These cells in the TME release abundant immunosuppressive signals, including PD-L1, transforming growth factor-beta (TGF-β ), and vascular endothelial growth factor, into the microenvironment and act directly or indirectly on effector T cells to suppress tumor immunity.”
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076 · see citing works
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · see citing works
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Zhang, Y., & Zhang, Z. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,815 · see citing works
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works
NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data
Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361 · see citing works
Breast cancer
Harbeck, N., & Gnant, M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,316 · see citing works
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238 · see citing works
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · see citing works
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189 · see citing works
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119 · see citing works
The IPD and IMGT/HLA database: allele variant databases
Robinson, J., Halliwell, J. A., Hayhurst, J. D., Flicek, P., Parham, P., & Marsh, S. G. E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1161 · Cited by 1,732 · see citing works
Therapeutic cancer vaccines
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581 · see citing works
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432 · see citing works
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06063-y · Cited by 1,432 · see citing works
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413 · see citing works
CCR7 and its ligands: balancing immunity and tolerance
Förster, R., Davalos-Misslitz, A. C., & Rot, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2297 · Cited by 1,410 · see citing works
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
Pitt, J. M., Marabelle, A., Eggermont, A. M. M., Soria, J., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,344 · see citing works
Humanized mice in translational biomedical research
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007) · Nature reviews. Immunology · doi:10.1038/nri2017 · Cited by 1,281 · see citing works
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243 · see citing works
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186 · see citing works
Therapeutic cancer vaccines
Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,182 · see citing works
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,113 · see citing works
Self-citation
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Robbins, P. F., Lu, Y., El‐Gamil, M., Li, Y. F., Gross, C. A., Gartner, J. J., Lin, J., Teer, J. K., Cliften, P. F., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,074 · see citing works
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2537-9 · Cited by 1,052 · see citing works
Identifying specificity groups in the T cell receptor repertoire
Glanville, J., Huang, H., Nau, A., Hatton, O., Wagar, L. E., Rubelt, F., Ji, X., Han, A., Krams, S. M., Pettus, C., et al. (2017) · Nature · doi:10.1038/nature22976 · Cited by 1,026 · see citing works
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020 · see citing works
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Yang, W., Bai, Y., Xiong, Y., Zhang, J., Chen, S., Zheng, X., Meng, X., Li, L., Wang, J., Xu, C., et al. (2016) · Nature · doi:10.1038/nature17412 · Cited by 1,010 · see citing works
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938 · see citing works
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
Lutsiak, M. E. C., Semnani, R. T., De Pascalis, R., Kashmiri, S. V. S., Schlom, J., & Sabzevari, H. (2005) · Blood · doi:10.1182/blood-2004-06-2410 · Cited by 903 · see citing works
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson‐Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 854 · see citing works
A guide to antigen processing and presentation
Pishesha, N., Harmand, T. J., & Ploegh, H. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00707-2 · Cited by 805 · see citing works
OptiType: precision HLA typing from next-generation sequencing data
Szolek, A., Schubert, B., Mohr, C., Sturm, M., Feldhahn, M., & Kohlbacher, O. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu548 · Cited by 762 · see citing works
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750 · see citing works
A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer
Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738 · see citing works
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 707 · see citing works
Neoantigen vaccine: an emerging tumor immunotherapy
Miao, P., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C. J., Wu, S., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 701 · see citing works
Plasmacytoid Dendritic Cells: Development, Regulation, and Function
Reizis, B. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.027 · Cited by 679 · see citing works
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
Kloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., Maus, M. V., Fraietta, J. A., Zhao, Y., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.003 · Cited by 648 · see citing works
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Gubin, M. M., Artyomov, M. N., Mardis, E. R., & Schreiber, R. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80008 · Cited by 608 · see citing works
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594 · see citing works
Two-step enhanced cancer immunotherapy with engineered <i>Salmonella typhimurium</i> secreting heterologous flagellin
Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588 · see citing works
Humanized Mouse Models of Clinical Disease
Walsh, N. C., Kenney, L. L., Jangalwe, S., Aryee, K., Greiner, D. L., Brehm, M. A., & Shultz, L. D. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100332 · Cited by 565 · see citing works
MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553 · see citing works
Identification of neoantigens for individualized therapeutic cancer vaccines
Lang, F., Schrörs, B., Löwer, M., Türeci, Ö., & Şahin, U. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00387-y · Cited by 553 · see citing works
A DNA nanodevice-based vaccine for cancer immunotherapy
Liu, S., Jiang, Q., Zhao, X., Zhao, R., Wang, Y., Wang, Y., Liu, J., Shang, Y., Zhao, S., Wu, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-020-0793-6 · Cited by 552 · see citing works
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
Hu, Z., Leet, D., Allesøe, R. L., Oliveira, G., Li, S., Luoma, A., Liu, J., Forman, J., Huang, T., Iorgulescu, J. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01206-4 · Cited by 550 · see citing works
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Butts, C. A., Socinski, M. A., Mitchell, P. L. R., Thatcher, N., Havel, L., Krzakowski, M. J., Nawrocki, S., Ciuleanu, T., Bosquée, L., Trigo, J. M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 539 · see citing works
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Mitchell, D. A., Batich, K. A., Gunn, M. D., Huang, M.-N., Sanchez-Perez, L. A., Nair, S. K., Congdon, K. L., Reap, E. A., Archer, G. E., Desjardins, A., et al. (2015) · Nature · doi:10.1038/nature14320 · Cited by 532 · see citing works
Addressing the Cold Reality of mRNA Vaccine Stability
Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W., & Mastrobattista, E. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.006 · Cited by 517 · see citing works
Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer
Mu, X., Shi, W. Q., Xu, Y., Xu, C., Zhao, T., Geng, B., Yang, J., Pan, J., Hu, S., Zhang, C., et al. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1444305 · Cited by 516 · see citing works
Self-citation
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Vansteenkiste, J., Cho, B. C., Vanakesa, T., Pas, T. M. D., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00099-1 · Cited by 512 · see citing works
Algorithm for optimized mRNA design improves stability and immunogenicity
Zhang, H., Zhang, L., Lin, A., Xu, C., Li, Z., Liu, K., Liu, B., Ma, X., Zhao, F., Jiang, H., et al. (2023) · Nature · doi:10.1038/s41586-023-06127-z · Cited by 498 · see citing works
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Boorjian, S. A., Mehrdad Alemozaffar, A., Konety, B. R., Shore, N. D., Gomella, L. G., Kamat, A. M., Bivalacqua, T. J., Montgomery, J. S., Lerner, S. P., Busby, J. E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30540-4 · Cited by 488 · see citing works
Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology
Cheng, K., Zhao, R., Li, Y., Qi, Y., Wang, Y., Zhang, Y., Qin, H., Qin, Y., Chen, L., Li, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22308-8 · Cited by 480 · see citing works
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Liau, L. M., Ashkan, K., Brem, S. S., Campian, J. L., Trusheim, J. E., IWAMOTO, F. M., Tran, D. D., Ansstas, G., Cobbs, C., Heth, J., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5370 · Cited by 471 · see citing works
The Intriguing History of Cancer Immunotherapy
Dobosz, P., & Dzieciątkowski, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02965 · Cited by 463 · see citing works
pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens
Hundal, J., Carreno, B. M., Petti, A. A., Linette, G. P., Griffith, O. L., Mardis, E. R., & Griffith, M. (2016) · Genome Medicine · doi:10.1186/s13073-016-0264-5 · Cited by 454 · see citing works
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi, J. L., Bobisse, S., Ophir, E., Tuyaerts, S., Roberti, A., Genolet, R., Baumgärtner, P., Stevenson, B. J., Iseli, C., Laniti, D. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao5931 · Cited by 453 · see citing works
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449 · see citing works
MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing
O’Donnell, T. J., Rubinsteyn, A., & Laserson, U. (2020) · Cell Systems · doi:10.1016/j.cels.2020.06.010 · Cited by 440 · see citing works
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Platten, M., Bunse, L., Wick, A., Bunse, T., Cornet, L. L., Harting, I., Sahm, F., Sanghvi, K., Tan, C. L., Poschke, I. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03363-z · Cited by 436 · see citing works
mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
Cafri, G., Gartner, J. J., Zaks, T., Hopson, K., Levin, N., Paria, B. C., Parkhurst, M. R., Yossef, R., Lowery, F. J., Jafferji, M. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134915 · Cited by 427 · see citing works
Humanized mouse models for immuno-oncology research
Chuprin, J., Buettner, H., Seedhom, M. O., Greiner, D. L., Keck, J. G., Ishikawa, F., Shultz, L. D., & Brehm, M. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00721-2 · Cited by 423 · see citing works
Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides
Zwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.350 · Cited by 416 · see citing works
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
Huang, L., Rong, Y., Tang, X., Yi, K., Qi, P., Hou, J., Liu, W., He, Y. Z., Gao, X., Yuan, C., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01515-x · Cited by 413 · see citing works
MHCflurry: Open-Source Class I MHC Binding Affinity Prediction
O’Donnell, T. J., Rubinsteyn, A., Bonsack, M., Riemer, A. B., Laserson, U., & Hammerbacher, J. (2018) · Cell Systems · doi:10.1016/j.cels.2018.05.014 · Cited by 410 · see citing works
Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases
Berman, T. A., & Schiller, J. T. (2017) · Cancer · doi:10.1002/cncr.30588 · Cited by 402 · see citing works
Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex
King, M. A., Covassin, L., Brehm, M. A., Racki, W. J., Pearson, T., Leif, J., Laning, J. C., Fodor, W. L., Foreman, O., Burzenski, L. M., et al. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03933.x · Cited by 389 · see citing works
Lipid nanoparticle technology for therapeutic gene regulation in the liver
Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.026 · Cited by 376 · see citing works
Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens
Lynn, G. M., Sedlik, C., Baharom, F., Zhu, Y., Ramirez-Valdez, R. A., Coble, V. L., Tobin, K. K. S., Nichols, S. R., Itzkowitz, Y., Zaidi, N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0390-x · Cited by 349 · see citing works
Macrophage MSR1 promotes BMSC osteogenic differentiation and M2-like polarization by activating PI3K/AKT/GSK3β/β-catenin pathway
Zhao, S.-J., Kong, F., Jian, J., Li, Q., Liu, H., Xu, A.-D., Yang, Y., Jiang, B., Wang, D., Zhou, Z., et al. (2019) · Theranostics · doi:10.7150/thno.36930 · Cited by 338 · see citing works
Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer
Eberhardt, C. S., Kissick, H. T., Patel, M. R., Cardenas, M. A., Prokhnevska, N., Obeng, R. C., Nasti, T. H., Griffith, C. C., Im, S. J., Wang, X., et al. (2021) · Nature · doi:10.1038/s41586-021-03862-z · Cited by 336 · see citing works
Cancer vaccines: Building a bridge over troubled waters
Sellars, M., Wu, C. J., & Fritsch, E. F. (2022) · Cell · doi:10.1016/j.cell.2022.06.035 · Cited by 322 · see citing works
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Bulik-Sullivan, B. K., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F. F., Yang, A., Young, L., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4313 · Cited by 311 · see citing works
pVACtools: A Computational Toolkit to Identify and Visualize Cancer Neoantigens
Hundal, J., Kiwala, S., McMichael, J. F., Miller, C. A., Wollam, A., Xia, H., Liu, C. J., Zhao, S., Feng, Y.-Y., Graubert, A., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0401 · Cited by 305 · see citing works
Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
Agliardi, G., Liuzzi, A. R., Hotblack, A., Feo, D. D., Núñez, N. G., Stowe, C., Friebel, E., Nannini, F., Rindlisbacher, L., Roberts, T. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20599-x · Cited by 303 · see citing works
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M. P., & Rivoltini, L. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl158 · Cited by 300 · see citing works
Plasmacytoid Dendritic Cells Transport Peripheral Antigens to the Thymus to Promote Central Tolerance
Hadeiba, H., Lahl, K., Edalati, A., Oderup, C., Habtezion, A., Pachynski, R. K., Nguyen, L. P., Ghodsi, A., Adler, S., & Butcher, E. C. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.017 · Cited by 292 · see citing works
Humanized Mice for the Study of Immuno-Oncology
Rochère, P. D. L., Guil‐Luna, S., Decaudin, D., Azar, G. A., Sidhu, S., & Piaggio, E. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.07.001 · Cited by 292 · see citing works
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Guo, Z. S., Lu, B., Guo, Z., Giehl, E., Feist, M., Dai, E., Liu, W., Storkus, W. J., He, Y., Liu, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0495-7 · Cited by 292 · see citing works
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., et al. (2015) · Journal for Immunotherapy of Cancer · doi:10.1186/s40425-015-0068-y · Cited by 287 · see citing works
DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires
Sidhom, J.-W., Larman, H. B., Pardoll, D. M., & Baras, A. S. (2021) · Nature Communications · doi:10.1038/s41467-021-21879-w · Cited by 286 · see citing works
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer
Ding, Z., Li, Q., Zhang, R., Xie, L., Shu, Y., Gao, S., Wang, P., Su, X., Qin, Y., Wang, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00448-5 · Cited by 270 · see citing works
Self-citation
HLA typing from RNA-Seq sequence reads
Boegel, S., Löwer, M., Schäfer, M. K. E., Bukur, T., de Graaf, J., Boisguérin, V., Türeci, Ö., Diken, M., Castle, J. C., & Şahin, U. (2012) · Genome Medicine · doi:10.1186/gm403 · Cited by 269 · see citing works
Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy
Liu, J.-Q., Zhang, C., Zhang, X., Yan, J., Zeng, C., Talebian, F., Lynch, K., Zhao, W., Hou, X., Du, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.021 · Cited by 267 · see citing works
Human dendritic cells in cancer
Kvedaraite, E., & Ginhoux, F. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm9409 · Cited by 261 · see citing works
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Palmer, C. D., Rappaport, A., Davis, M. J., Hart, M. G., Scallan, C. D., Hong, S., Gitlin, L., Kraemer, L. D., Kounlavouth, S., Yang, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01937-6 · Cited by 249 · see citing works
Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response
Yu, X. M., Dai, Y., Zhao, Y., Qi, S., Liu, L., Lu, L., Luo, Q., & Zhang, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-14906-9 · Cited by 246 · see citing works
Pan-Specific Prediction of Peptide–MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity
Rasmussen, M., Fenoy, E., Harndahl, M. N., Kristensen, A. B., Nielsen, I. K., Nielsen, M., & Buus, S. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600582 · Cited by 241 · see citing works
Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity
Suschak, J. J., Williams, J. A., & Schmaljohn, C. S. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1330236 · Cited by 240 · see citing works
Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction
Abelin, J. G., Harjanto, D., Malloy, M., Suri, P., Colson, T. R., Goulding, S. P., Creech, A. L., Serrano, L. R., Nasir, G., Nasrullah, Y., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.012 · Cited by 240 · see citing works
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
Awad, M. M., Govindan, R., Balogh, K. N., Spigel, D. R., Garon, E. B., Bushway, M. E., Poran, A., Sheen, J. H., Kohler, V. L., Esaulova, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.003 · Cited by 238 · see citing works
Development of an In Situ Cancer Vaccine via Combinational Radiation and Bacterial‐Membrane‐Coated Nanoparticles
Patel, R. B., Ye, M., Carlson, P. M., Jaquish, A. A., Zangl, L. M., Ma, B., Wang, Y., Arthur, I. S., Xie, R., Brown, R. J., et al. (2019) · Advanced Materials · doi:10.1002/adma.201902626 · Cited by 233 · see citing works
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Chen, F., Zou, Z., Du, J., Su, S., Shao, J., Meng, F., Yang, J. D., Xu, Q., Ding, N., Yang, Y., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci99538 · Cited by 232 · see citing works
Self-citation
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
Wang, G., Kang, X., Chen, K. S., Jehng, T., Jones, L. E., Chen, J., Huang, X. F., & Chen, S. (2020) · Nature Communications · doi:10.1038/s41467-020-15229-5 · Cited by 229 · see citing works
Peptide‐ MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity
Harndahl, M. N., Rasmussen, M., Røder, G., Pedersen, I. D., Sørensen, M., Nielsen, M., & Buus, S. (2012) · European Journal of Immunology · doi:10.1002/eji.201141774 · Cited by 219 · see citing works
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses
Welters, M. J. P., van der Sluis, T. C., van Meir, H., Loof, N. M., van Ham, V. J., van Duikeren, S., Santegoets, S. J. A. M., Arens, R., de Kam, M. L., Cohen, A. F., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8307 · Cited by 216 · see citing works
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Mittendorf, E. A., Lu, B., Melisko, M., Hiller, J. A. P., Bondarenko, I., Brunt, A. M., Sergii, G., Petráková, K., & Peoples, G. E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2867 · Cited by 214 · see citing works
A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
Ramlau, R., Quoix, É., Rolski, J., Pless, M., Léna, H., Lévy, E., Krzakowski, M. J., Hess, D., Tartour, É., Chenard, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c6b4f · Cited by 209 · see citing works
Expression of HLA Class II Molecules in Humanized NOD.Rag1KO.IL2RgcKO Mice Is Critical for Development and Function of Human T and B Cells
Danner, R., Chaudhari, S. N., Rosenberger, J., Surls, J., Richie, T. L., Brumeanu, T., & Casares, S. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019826 · Cited by 206 · see citing works
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
Dréno, B., Thompson, J. F., Smithers, B. M., Santinami, M., Jouary, T., Gutzmer, R., Levchenko, E., Rutkowski, P. L., Grob, J., Korovin, S. I., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30254-7 · Cited by 204 · see citing works
The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification
Jou, J., Harrington, K. J., Zocca, M.-B., Ehrnrooth, E., & Cohen, E. E. W. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0245 · Cited by 203 · see citing works
Peptide‐based therapeutic cancer vaccine: Current trends in clinical application
Liu, W., Tang, H., Li, L., Wang, X., Yu, Z., & Li, J. (2021) · Cell Proliferation · doi:10.1111/cpr.13025 · Cited by 200 · see citing works
Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
Nakao, S., Arai, Y., Tasaki, M., YAMASHITA, M., Murakami, R., Kawase, T., Amino, N., Nakatake, M., Kurosaki, H., Mori, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7992 · Cited by 191 · see citing works
A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
Taylor, G. S., Jia, H., Harrington, K. J., Lee, L. W., Turner, J., Ladell, K., Price, D. A., Tanday, M., Matthews, J., Roberts, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1122-t · Cited by 189 · see citing works
Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination
Persano, S., Guevara, M. L., Li, Z., Mai, J., Ferrari, M., Pompa, P. P., & Shen, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.019 · Cited by 187 · see citing works
Antigen kinetics determines immune reactivity
Johansen, P., Storni, T., Rettig, L., Qiu, Z., Der-Sarkissian, A., Smith, K. A., Manolova, V., Lang, K. S., Senti, G., Müllhaupt, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706296105 · Cited by 184 · see citing works
Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells
Bu, W., Joyce, M. G., Nguyen, H., Banh, D. V., Aguilar, F., Tariq, Z., Yap, M. L., Tsujimura, Y., Gillespie, R. A., Tsybovsky, Y., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.010 · Cited by 181 · see citing works
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
Westcott, P. M. K., Sacks, N. J., Schenkel, J. M., Ely, Z. A., Smith, O. C. G., Hauck, H., Jaeger, A. M., Zhang, D., Backlund, C. M., Beytagh, M. C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00247-z · Cited by 180 · see citing works
Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases
Cui, X., & Snapper, C. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734471 · Cited by 179 · see citing works
Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
He, J., Xiong, X., Yang, H., Li, D., Liu, X., Li, S., Liao, S., Chen, S., Wen, X., Yu, K., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00627-9 · Cited by 179 · see citing works
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial
Youn, J. W., Hur, S. Y., Woo, J. W., Kim, Y., Lim, M. C., Park, S., Seo, S. S., No, J. H., Kim, B., Lee, J. K., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30486-1 · Cited by 176 · see citing works
A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction
Mei, S., Li, F., Leier, A., Marquez‐Lago, T. T., Giam, K., Croft, N. P., Akutsu, T., Smith, A. I., Li, J., Rossjohn, J., et al. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz051 · Cited by 171 · see citing works
Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Viaud, S., Flament, C., Zoubir, M., Pautier, P., LeCesne, A., Ribrag, V., Soria, J.-C., Marty, V., Vielh, P., Robert, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1259 · Cited by 170 · see citing works
Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes
Zhao, W., & Sher, X. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006457 · Cited by 169 · see citing works
TITAN: T-cell receptor specificity prediction with bimodal attention networks
Weber, A., Born, J., & Martínez, M. R. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab294 · Cited by 169 · see citing works
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
Keersmaecker, B. D., Claerhout, S., Carrasco, J., Bar, I., Corthals, J., Wilgenhof, S., Neyns, B., & Thielemans, K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000329 · Cited by 168 · see citing works
TCRMatch: Predicting T-Cell Receptor Specificity Based on Sequence Similarity to Previously Characterized Receptors
Chronister, W. D., Crinklaw, A., Mahajan, S., Vita, R., Koşaloğlu‐Yalçın, Z., Zhen, Y., Greenbaum, J., Jessen, L. E., Nielsen, M., Christley, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640725 · Cited by 168 · see citing works
mRNA cancer vaccines: Advances, trends and challenges
He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 167 · see citing works
The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
Danilova, L., Anagnostou, V., Caushi, J. X., Sidhom, J.-W., Guo, H., Chan, H. Y., Suri, P., Tam, A. J., Zhang, J., Asmar, M. E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0129 · Cited by 166 · see citing works
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
Pai, J. A., Hellmann, M. D., Sauter, J. L., Mattar, M. S., Rizvi, H. A., Woo, H. J., Shah, N., Nguyen, E. M., Uddin, F. Z., Quintanal-Villalonga, À., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.009 · Cited by 161 · see citing works
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group
Mattos‐Arruda, L. D., Vázquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 159 · see citing works
Pan-Peptide Meta Learning for T-cell receptor–antigen binding recognition
Gao, Y., Gao, Y., Fan, Y., Zhu, C., Wei, Z., Zhou, C., Chuai, G., Chen, Q., Zhang, H., & Liu, Q. (2023) · Nature Machine Intelligence · doi:10.1038/s42256-023-00619-3 · Cited by 155 · see citing works
Antigen processing and presentation in cancer immunotherapy
Lee, M. Y., Jeon, J. W., Sievers, C. M., & Allen, C. T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001111 · Cited by 153 · see citing works
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses
Zuo, B., Zhang, Y., Zhao, K., Wu, L., Han, Q., Yang, R., Gao, X., Geng, M., Wu, Y., Jing, R., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01266-8 · Cited by 153 · see citing works
A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma
Chia, W. K., Wang, W.-W., Teo, M. C. C., Tai, W., Lim, W., Tan, E. H., Leong, S. S., Sun, L., Chen, J. J., Gottschalk, S. M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr341 · Cited by 147 · see citing works
A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial
Kloor, M., Reuschenbach, M., Pauligk, C., Karbach, J., Rafiyan, M., Al‐Batran, S., Tariverdian, M., Jäger, E., & Doeberitz, M. V. K. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3517 · Cited by 146 · see citing works
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E4697)
Lawson, D. H., Lee, S., Zhao, F., Tarhini, A. A., Margolin, K. A., Ernstoff, M. S., Atkins, M. B., Cohen, G. I., Whiteside, T. L., Butterfield, L. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0500 · Cited by 141 · see citing works
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival
Melief, C. J. M., Welters, M. J. P., Vergote, I., Kroep, J. R., Kenter, G. G., Ottevanger, P. B., Tjalma, W. A. A., Denys, H., van Poelgeest, M. I. E., Nijman, H. W., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8235 · Cited by 134 · see citing works
A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity
Yang, R., Deng, Y., Huang, B., Huang, L., Lin, A., Li, Y., Wang, W., Liu, J., Lu, S., Zhan, Z., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00634-z · Cited by 130 · see citing works
Next-generation peptide vaccines for advanced cancer
Yamada, A., Sasada, T., Noguchi, M., & Itoh, K. (2013) · Cancer Science · doi:10.1111/cas.12050 · Cited by 124 · see citing works
Immunotherapy targeting HPV 16/18 generates potent immune responses in HPV-Associated Head and Neck Cancer
Aggarwal, C., Cohen, R., Morrow, M., Kraynyak, K., Sylvester, A., Knoblock, D., Bauml, J., Weinstein, G., Lin, A., Boyer, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1763 · Cited by 124 · see citing works
Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
Cai, Z., Su, X., Qiu, L., Li, Z., Li, X., Dong, X., Wei, F., Zhou, Y., Luo, L., Chen, G., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01467-8 · Cited by 123 · see citing works
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma
Mueller, S., Taitt, J. M., Villanueva-Meyer, J. E., Bonner, E. R., Nejo, T., Lulla, R. R., Goldman, S., Banerjee, A., Chi, S. N., Whipple, N. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140378 · Cited by 121 · see citing works
Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial
Driessche, A. V., de Velde, A. L. R. V., Nijs, G., Braeckman, T., Stein, B., de Vries, I. J. M., Berneman, Z. N., & Tendeloo, V. F. V. (2009) · Cytotherapy · doi:10.1080/14653240902960411 · Cited by 116 · see citing works
HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory
Grunwitz, C. R., Salomon, N., Vascotto, F., Selmi, A., Bukur, T., Diken, M., Kreiter, S., Türeci, Ö., & Şahin, U. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629259 · Cited by 114 · see citing works
Identification of CCR9− murine plasmacytoid DC precursors with plasticity to differentiate into conventional DCs
Schlitzer, A., Loschko, J., Mair, K., Vogelmann, R., Henkel, L., Einwächter, H., Schiemann, M., Niess, J. H., Reindl, W., & Krug, A. (2011) · Blood · doi:10.1182/blood-2010-12-326678 · Cited by 113 · see citing works
INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery
Zhang, J., Mardis, E. R., & Maher, C. A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw674 · Cited by 113 · see citing works
mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response
Tse, S., McKinney, K. M., Walker, W., Nguyen, M., Iacovelli, J., Small, C. G., Hopson, K., Zaks, T. Z., & Huang, E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.002 · Cited by 113 · see citing works
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses
Mitchell, P., Thatcher, N., Socinski, M. A., Wasilewska-Teśluk, E., Horwood, K., Szczęsna, A., Martin, C. M., Ragulin, Y. А., Zukin, M., Helwig, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv104 · Cited by 111 · see citing works
Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy
Bonaventura, P., Alcazer, V., Mutez, V., Tonon, L., Martin, J., Chuvin, N., Michel, E., Boulos, R. E., Estornes, Y., Valladeau‐Guilemond, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj3671 · Cited by 110 · see citing works
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives
Chen, X., Yang, J. D., Wang, L., & Liu, B. (2020) · Theranostics · doi:10.7150/thno.38742 · Cited by 109 · see citing works
Self-citation
HLAscan: genotyping of the HLA region using next-generation sequencing data
Ka, S., Lee, S., Hong, J., Cho, Y., Sung, J., Kim, H., Kim, H., & Jung, J. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1671-3 · Cited by 108 · see citing works
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer
Heery, C. R., Ibrahim, N. K., Arlen, P. M., Mohebtash, M., Murray, J. L., Koenig, K. B., Madan, R. A., McMahon, S., Marté, J. L., Steinberg, S. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2736 · Cited by 106 · see citing works
DLpTCR: an ensemble deep learning framework for predicting immunogenic peptide recognized by T cell receptor
Xu, Z., Luo, M., Lin, W., Xue, G., Wang, P., Jin, X., Xu, C., Zhou, W., Cai, Y., Yang, W., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab335 · Cited by 105 · see citing works
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer
Disis, M. L., Guthrie, K. A., Liu, Y., Coveler, A. L., Higgins, D. M., Childs, J. S., Dang, Y., & Salazar, L. G. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5143 · Cited by 100 · see citing works
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Sobhani, N., Scaggiante, B., Morris, R. M., Chai, D., Catalano, M., Tardiel-Cyril, D. R., Neeli, P. K., Roviello, G., Mondani, G., & Li, Y. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102429 · Cited by 99 · see citing works
Advances in dendritic cell vaccination therapy of cancer
Najafi, S., & Mortezaee, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114954 · Cited by 98 · see citing works
Direct Presentation of Tumor‐Associated Antigens to Induce Adaptive Immunity by Personalized Dendritic Cell‐Mimicking Nanovaccines
Zhang, J., Fan, B., Cao, G., Huang, W., Jia, F., Nie, G., & Wang, H. (2022) · Advanced Materials · doi:10.1002/adma.202205950 · Cited by 97 · see citing works
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
Clifton, G. T., Hale, D. F., Vreeland, T. J., Hickerson, A. T., Litton, J. K., Alatrash, G., Murthy, R. K., Qiao, N., Philips, A. V., Lukas, J. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2741 · Cited by 95 · see citing works
Protamine-Based Strategies for RNA Transfection
Jarzebska, N. T., Mellett, M., Frei, J., Kündig, T. M., & Pascolo, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060877 · Cited by 95 · see citing works
Kourami: graph-guided assembly for novel human leukocyte antigen allele discovery
Lee, H., & Kingsford, C. (2018) · Genome biology · doi:10.1186/s13059-018-1388-2 · Cited by 93 · see citing works
High-Accuracy HLA Type Inference from Whole-Genome Sequencing Data Using Population Reference Graphs
Dilthey, A., Gourraud, P., Mentzer, A. J., Cereb, N., Iqbal, Z., & McVean, G. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005151 · Cited by 92 · see citing works
pTuneos: prioritizing tumor neoantigens from next-generation sequencing data
Zhou, C., Wei, Z., Zhang, Z., Zhang, B., Zhu, C., Chen, K., Chuai, G., Qu, S., Xie, L., Gao, Y., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0679-x · Cited by 89 · see citing works
Adenovirus Vector System: Construction, History and Therapeutic Applications
Syyam, A., Nawaz, A., Ijaz, A., Sajjad, U., Fazil, A., Irfan, S., Muzaffar, A., Shahid, M., Idrees, M., Malik, K. A., et al. (2022) · BioTechniques · doi:10.2144/btn-2022-0051 · Cited by 88 · see citing works
TIminer: NGS data mining pipeline for cancer immunology and immunotherapy
Tappeiner, E., Finotello, F., Charoentong, P., Mayer, C., Rieder, D., & Trajanoski, Z. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx377 · Cited by 86 · see citing works
Gene fusion neoantigens: Emerging targets for cancer immunotherapy
Wang, Y., Shi, T., Song, X., Liu, B., & Wei, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.023 · Cited by 86 · see citing works
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
Engelhard, V. H., Obeng, R. C., Cummings, K. L., Petroni, G. R., Ambakhutwala, A. L., Chianese‐Bullock, K. A., Smith, K. T., Lulu, A. M., Varhegyi, N., Smolkin, M. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000262 · Cited by 85 · see citing works
Cytosolic nucleic acid sensors and innate immune regulation
Ori, D., Murase, M., & Kawai, T. (2017) · International Reviews of Immunology · doi:10.1080/08830185.2017.1298749 · Cited by 84 · see citing works
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial
Romano, E., Michielin, O. A., Voelter, V., Laurent, J., Bichat, H., Stravodimou, A., Romero, P. J., Speiser, D. E., Triebel, F., Leyvraz, S., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-97 · Cited by 82 · see citing works
MAGE-A antigens as targets for cancer immunotherapy
Schooten, E., Maggio, A. D., Henegouwen, P. M. P. V. B. E., & Kijanka, M. M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.009 · Cited by 82 · see citing works
Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity
Chen, K., Reinshagen, C., van Schaik, T., Rossignoli, F., Borges, P., Mendonca, N. C., Abdi, R., Simon, B. G., Reardon, D. A., Wakimoto, H., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo4778 · Cited by 80 · see citing works
A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment
Chen, Z., Zhang, S., Han, N., Jiang, J., Xu, Y., Ma, D., Lu, L., Guo, X., Qiu, M. R., Huang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691605 · Cited by 79 · see citing works
FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines
Kreiter, S., Diken, M., Selmi, A., Diekmann, J., Attig, S., Hüsemann, Y., Koslowski, M., Huber, C., Türeci, Ö., & Şahin, U. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0291 · Cited by 78 · see citing works
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial
Soliman, H. H., Hogue, D., Han, H. S., Mooney, B. P., Costa, R. L. B., Lee, M. C., Niell, B. L., Williams, A. R., Chau, A., Falcon, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02210-0 · Cited by 78 · see citing works
Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines
Oladejo, M., Paulishak, W., & Wood, L. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.003 · Cited by 74 · see citing works
AN ECONOMICAL REGIMEN OF HUMAN DIPLOID CELL STRAIN ANTI-RABIES VACCINE FOR POST-EXPOSURE PROPHYLAXIS
Warrell, M. J., Suntharasamai, P., Sinhaseni, A., Phanfung, R., Jc, V.-F., BUNNAG, D., Warrell, D. A., Viravan, C., Udomsakdi, D., Xueref, C., et al. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90288-x · Cited by 72 · see citing works
The effect of antigen dose on T cell-targeting vaccine outcome
Billeskov, R., Beikzadeh, B., & Berzofsky, J. A. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1527496 · Cited by 72 · see citing works
Cancer/testis antigens: from serology to mRNA cancer vaccine
Fan, C., Qu, H., Wang, X., Sobhani, N., Wang, L., Liu, S., Xiong, W., Zeng, Z., & Li, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.016 · Cited by 72 · see citing works
Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo
Chang, D.-K., Moniz, R. J., Xu, Z., Sun, J., Signoretti, S., Zhu, Q. K., & Marasco, W. A. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0384-3 · Cited by 70 · see citing works
Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors
Harrison, R. P., Ruck, S., Rafiq, Q. A., & Medcalf, N. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.12.013 · Cited by 70 · see citing works
Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets
Duinkerken, S., Horrevorts, S. K., Kalay, H., Ambrosini, M., Rutte, L., de Gruijl, T. D., García-Vallejo, J. J., & van Kooyk, Y. (2019) · Theranostics · doi:10.7150/thno.35059 · Cited by 68 · see citing works
Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment
Feola, S., Russo, S., Ylösmäki, E. O., & Cerullo, V. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108103 · Cited by 67 · see citing works
epiTCR: a highly sensitive predictor for TCR–peptide binding
Pham, M.-D. N., Nguyen, T.-N., Tran, L. S., Nguyen, Q.-T. B., Nguyen-Hoang, T.-P., Pham, T. M. Q., Nguyen, H., Giang, H., Phan, M., & Nguyen, V. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad284 · Cited by 67 · see citing works
NetTCR-2.1: Lessons and guidance on how to develop models for TCR specificity predictions
Montemurro, A., Jessen, L. E., & Nielsen, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1055151 · Cited by 66 · see citing works
Lymphoid tissue–specific homing of bone marrow–derived dendritic cells
Creusot, R. J., Yaghoubi, S. S., Chang, P. P., Chia, J. X., Contag, C. H., Gambhir, S. S., & Fathman, C. G. (2009) · Blood · doi:10.1182/blood-2009-02-204321 · Cited by 65 · see citing works
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Teixeira, L., Médioni, J., Garibal, J., Adotévi, O., Doucet, L. S., Dragon‐Durey, M., Ghrieb, Z., Kiladjian, J., Brizard, M., Laheurte, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1614 · Cited by 65 · see citing works
CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy
Xu, J., Liu, H., Wang, T., Wen, Z., Chen, H., Yang, Z., Li, L., Yu, S., Gao, S., Yang, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202207017 · Cited by 65 · see citing works
Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial
Elizaga, M. L., Li, S. S., Kochar, N. K., Wilson, G. J., Allen, M., Tieu, H., Frank, I., Sobieszczyk, M. E., Cohen, K. W., Sanchez, B., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202753 · Cited by 63 · see citing works
Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma
Chu, Y., Qian, L., Ke, Y., Feng, X., Chen, X., Liu, F., Yu, L., Zhang, L., Tao, Y., Xu, R. C., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01397-7 · Cited by 63 · see citing works
PHLAT: Inference of High-Resolution HLA Types from RNA and Whole Exome Sequencing
Bai, Y., Wang, D., & Fury, W. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8546-3_13 · Cited by 61 · see citing works
Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
Wargowski, E., Johnson, L. E., Eickhoff, J. C., Delmastro, L. E., Staab, M. J., Liu, G., & McNeel, D. G. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0333-y · Cited by 59 · see citing works
Engineering chimeric antigen receptor T cells for solid tumour therapy
Liu, L., Qu, Y., Cheng, L., Yoon, C. W., He, P., Monther, A., Guo, T., Chittle, S. J., & Wang, Y. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1141 · Cited by 59 · see citing works
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial
Shing, J. Z., Hu, S., Herrero, R., Hildesheim, A., Porras, C., Sampson, J. N., Schussler, J. E., Schiller, J. T., Lowy, D. R., Sierra, M. S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00291-1 · Cited by 58 · see citing works
Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma
Steele, J., Rao, A., Marsden, J., Armstrong, C., Berhane, S., Billingham, L., Graham, N., Roberts, C., Ryan, G., Uppal, H., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.1 · Cited by 57 · see citing works
Toward in silico Identification of Tumor Neoantigens in Immunotherapy
Zhou, C., Zhu, C., & Liu, Q. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.08.001 · Cited by 57 · see citing works
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57 · see citing works
Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial
Soliman, H. H., Hogue, D., Han, H. S., Mooney, B. P., Costa, R. L. B., Lee, M. C., Niell, B. L., Williams, A. R., Chau, A., Falcon, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02309-4 · Cited by 57 · see citing works
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
Patel, S. P., Petroni, G. R., Roszik, J., Olson, W. C., Wages, N. A., Chianese‐Bullock, K. A., Smolkin, M. E., Varhegyi, N., Gaughan, E. M., Smith, K. T., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003220 · Cited by 56 · see citing works
The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy?
Alsalloum, A., Shevchenko, J. A., & Sennikov, S. V. (2023) · Cancers · doi:10.3390/cancers15061779 · Cited by 56 · see citing works
T cell memory and protective immunity by vaccination: is more better?
Zanetti, M., & Franchini, G. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.09.004 · Cited by 55 · see citing works
Integrated mRNA sequence optimization using deep learning
Gong, H., Wen, J., Luo, R., Feng, Y., Guo, J., Fu, H., & Zhou, X. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad001 · Cited by 53 · see citing works
Precursor Frequency and Competition Dictate the HLA-A2–Restricted CD8+ T Cell Responses to Influenza A Infection and Vaccination in HLA-A2.1 Transgenic Mice
Tan, A. C. L., Gruta, N. L. L., Zeng, W., & Jackson, D. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100664 · Cited by 51 · see citing works
High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions
Blaha, D. T., Anderson, S. D., Yoakum, D. M., Hager, M. V., Zha, Y., Gajewski, T. F., & Kranz, D. M. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0395 · Cited by 51 · see citing works

Flagged first, then by citations

Research works printed but not linked: 1

[224]Ott, P. et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung. Cancer, or Bladder. Cancer 183, 347–362 (2020). 33064988

Sorted by citations

Current and future immunotherapeutic approaches in pancreatic cancer treatment
Farhangnia, P., Khorramdelazad, H., Nickho, H., & Delbandi, A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01561-6 · Cited by 247 · see citing works
Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery
Tenchov, R., Hughes, K. J., Ganesan, M., Iyer, K. A., Ralhan, K., Diaz, L. M. L., Bird, R. E., Ivanov, J. M., & Zhou, Q. A. (2025) · ACS Nano · doi:10.1021/acsnano.4c09566 · Cited by 149 · see citing works
Clinical advances of mRNA vaccines for cancer immunotherapy
Yaremenko, A. V., Khan, M. M., Zhen, X., Tang, Y., & Tao, W. (2025) · Med · doi:10.1016/j.medj.2024.11.015 · Cited by 127 · see citing works
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment
Garg, P. K., Pareek, S., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216537 · Cited by 123 · see citing works
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 116 · see citing works
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Yu, B., Shao, S., & Ma, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217350 · Cited by 112 · see citing works
Resident memory T cells and cancer
Gavil, N. V., Cheng, K., & Masopust, D. (2024) · Immunity · doi:10.1016/j.immuni.2024.06.017 · Cited by 94 · see citing works
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives
Sun, S., Liu, L., Zhang, J., Sun, L., Shu, W., Yang, Z., Yao, H., & Zhang, Z. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01732-z · Cited by 84 · see citing works
Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform ‘cold’ tumors into ‘hot’ tumors
Ying, X., Chen, Q., Yang, Y., Wu, Z., Zeng, W., Miao, C., Huang, Q., & Ai, K. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02186-6 · Cited by 86 · see citing works
Advanced Polymeric Nanoparticles for Cancer Immunotherapy: Materials Engineering, Immunotherapeutic Mechanism and Clinical Translation
Jia, W., Wu, Y., Xie, Y., Yu, M., & Chen, Y. (2025) · Advanced Materials · doi:10.1002/adma.202413603 · Cited by 74 · see citing works
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 66 · see citing works
Cancer vaccines: Target antigens, vaccine platforms and preclinical models
Ruzzi, F., Riccardo, F., Conti, L., Tarone, L., Semprini, M. S., Bolli, E., Barutello, G., Quaglino, E., Lollini, P., & Cavallo, F. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101324 · Cited by 64 · see citing works
Immunotherapy in microsatellite-stable colorectal cancer: Strategies to overcome resistance
Chen, E., & Zhou, W. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104775 · Cited by 66 · see citing works
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 69 · see citing works
Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
Fan, T., Xu, C., Wu, J., Cai, Y., Cao, W., Shen, H., Zhang, M., Zhu, H., Yang, J., Zhu, Z., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn9961 · Cited by 61 · see citing works
Self-citation
Extracellular vesicles-based vaccines: Emerging immunotherapies against cancer
Meng, Y., Yao, Z., Ke, X., Hu, M., Ren, H., Gao, S., & Zhang, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.010 · Cited by 57 · see citing works
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 57 · see citing works
Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions
Aljabali, A. A. A., Obeid, M. A., Gammoh, O., El‐Tanani, M., Mishra, V. K., Mishra, Y., Kapre, S., Palakurthi, S. S., Hassan, S. S., Nawn, D., et al. (2024) · Cancers · doi:10.3390/cancers16112030 · Cited by 55 · see citing works
mRNA vaccines: a new era in vaccine development
Chandra, S., Wilson, J. C., Good, D. M., & Wei, M. Q. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.043987 · Cited by 58 · see citing works
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 56 · see citing works
Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect
Kwon, W., & Joung, J. Y. (2025) · Cancers · doi:10.3390/cancers17071064 · Cited by 47 · see citing works
The Platform Technology Approach to mRNA Product Development and Regulation
Skerritt, J. H., Tucek, C. L., Sutton, B. A., & Nolan, T. M. (2024) · Vaccines · doi:10.3390/vaccines12050528 · Cited by 46 · see citing works
Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition
Yoo, H., Kim, Y., Kim, J., Cho, H., & Kim, K. (2024) · Molecules · doi:10.3390/molecules29173994 · Cited by 46 · see citing works
Apolipoprotein Fusion Enables Spontaneous Functionalization of mRNA Lipid Nanoparticles with Antibody for Targeted Cancer Therapy
Park, W., Choi, J., Hwang, J., Kim, S. H., Kim, Y., Shim, M. K., Park, W., Yu, S., Jung, S., Yang, Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16562 · Cited by 46 · see citing works
Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination
Zhou, Z., Mai, Y., Zhang, G., Wang, Y., Sun, P., Jing, Z., Li, Z., Xu, Y., Han, B. R., & Liu, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217079 · Cited by 42 · see citing works
Advances in nucleic acid-based cancer vaccines
Liao, H., & Liu, S. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01102-w · Cited by 45 · see citing works
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works
Recent progress in cancer vaccines and nanovaccines
Poudel, K., Vithiananthan, T., Kim, J. O., & Tsao, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122856 · Cited by 40 · see citing works
Boosting CAR-T cell therapy through vaccine synergy
Li, Y.-R., Lyu, Z., Shen, X., Fang, Y., & Yang, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.004 · Cited by 38 · see citing works
An OMV‐Based Nanovaccine as Antigen Presentation Signal Enhancer for Cancer Immunotherapy
Lu, Y., Ma, N., Cheng, K., Liu, G., Liang, J., Chen, X., Li, D., Cao, C., Gao, X., Chen, L., et al. (2025) · Advanced Materials · doi:10.1002/adma.202413392 · Cited by 38 · see citing works
mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy
Haghmorad, D., Eslami, M., Orooji, N., Halabitska, I., Kamyshna, I. I., Kamyshnyi, O., & Oksenych, V. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1547025 · Cited by 39 · see citing works
Lnc-H19-derived protein shapes the immunosuppressive microenvironment of glioblastoma
Chen, J., Gao, Y., Zhong, J., Wu, X., Leng, Z., Liu, M., Wang, Y., Wang, Y., Yang, X., Huang, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101806 · Cited by 34 · see citing works
Self-citation
Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma
Yan, P., Wang, J., Yue, B., & Wang, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189171 · Cited by 31 · see citing works
Nanobiotechnology boosts ferroptosis: opportunities and challenges
Han, S., Zou, J., Xiao, F., Xian, J., Liu, Z., Li, M., Luo, W., Feng, C., & Kong, N. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02842-5 · Cited by 32 · see citing works
In Silico-Guided Discovery of Polysaccharide Derivatives as Adjuvants in Nanoparticle Vaccines for Cancer Immunotherapy
Cui, Z., Shi, C., An, R., Tang, Y., Li, Y., Cao, X., Jiang, X., Liu, C., Xiao, M., & Xu, L. (2025) · ACS Nano · doi:10.1021/acsnano.4c08898 · Cited by 29 · see citing works
Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies
Arecco, L., Leite, L. D. M., Gentile, G., Janković, K., Stana, M., Ottonello, S., Scavone, G., Spinaci, S., & Lambertini, M. (2025) · Human Reproduction · doi:10.1093/humrep/deaf096 · Cited by 31 · see citing works
Bioengineering Outer-Membrane Vesicles for Vaccine Development: Strategies, Advances, and Perspectives
Zahid, A., Ismail, H., Wilson, J. C., & Grice, I. D. (2025) · Vaccines · doi:10.3390/vaccines13070767 · Cited by 29 · see citing works
Boosting vaccine effectiveness: The groundbreaking role of probiotics
Abavisani, M., Ebadpour, N., Khoshrou, A., & Sahebkar, A. (2024) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2024.101189 · Cited by 29 · see citing works
Porphyrins and Their Derivatives in Cancer Therapy: Current Advances, Mechanistic Insights, and Prospective Directions.
Chen, M., Ji, S., Liu, X.-X., Zheng, X., Zhou, M.-J., & Wang, W.-Q. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01359 · Cited by 27 · see citing works
Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives
Miao, H., Yuan, F., Pan, C.-X., Yang, H., Wang, Z., Qi, Y., Wu, Y. Z., Zhang, Y., Liu, F., Huang, H., et al. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100087 · Cited by 31 · see citing works
The key role of matrix stiffness in colorectal cancer immunotherapy: mechanisms and therapeutic strategies
Chen, E., Zeng, Z., & Zhou, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189198 · Cited by 29 · see citing works
Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer
Skaličková, M., Vanova, K. H., Uher, O., Fialová, J. L., Petrláková, K., Masařík, M., Kejík, Z., Pavel Martasek, E., Pacák, K., & Jakubek, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1479483 · Cited by 27 · see citing works
Harnessing phytochemicals: Innovative strategies to enhance cancer immunotherapy
Zhu, Q., Zhang, R., Zhao, Z., Xie, T., & Sui, X. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101206 · Cited by 28 · see citing works
Reprogramming cancer immunity with next-generation combination therapies
Kyriakidis, N. C., Echeverría, C. E., Bautista, J., Rivera-Orellana, S., Ramos-Medina, M. J., Salazar-Santoliva, C., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Guerrero, S. X., & López‐Cortés, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1652047 · Cited by 27 · see citing works
Combining Photodynamic Therapy and Targeted Drug Delivery Systems: Enhancing Mitochondrial Toxicity for Improved Cancer Outcomes
Merlin, J. P. J., Crous, A., & Abrahamse, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910796 · Cited by 25 · see citing works
Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens
Chi, W.-Y., Hu, Y., Huang, H., Kuo, H., Lin, S., Kuo, C.-T. J., Tao, J., Fan, D., Huang, Y.-M., Wu, A. A., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01082-x · Cited by 26 · see citing works
Translational Advances in Oncogene and Tumor-Suppressor Gene Research
Stojchevski, R., Sutanto, E. A., Sutanto, R., Hadzi‐Petrushev, N., Mladenov, M. I., Singh, S. P., Sinha, J. K., Ghosh, S., Yarlagadda, B., Singh, D. K. K., et al. (2025) · Cancers · doi:10.3390/cancers17061008 · Cited by 30 · see citing works
State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers
Strum, S. W., Andersen, M. H., Svane, I. M., Siu, L. L., & Weber, J. S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438592 · Cited by 24 · see citing works
Remodeling tumor immunosuppressive microenvironment through dual activation of immunogenic panoptosis and ferroptosis by H2S-amplified nanoformulation to enhance cancer immunotherapy
Luo, Y., Linghu, M., Luo, X., Li, D., Wang, J., Peng, S., & Ma, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.014 · Cited by 24 · see citing works
Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials
Hussain, Z. B., Zhang, Y., Qiu, L., Gou, S., & Liu, K. (2025) · npj Vaccines · doi:10.1038/s41541-025-01084-2 · Cited by 24 · see citing works
Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model
Nguyen, C. M., Vu, T. T., Nguyen, M. N., Tran-Nguyen, T.-S., Huynh, C. T., Ha, Q. T., Nguyen, H., & Tran, L. S. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03992-7 · Cited by 24 · see citing works
Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions
Xu, S., Yang, H., Minev, B., & Ma, W. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.01.070 · Cited by 24 · see citing works
Advancing the Fight Against Cervical Cancer: The Promise of Therapeutic HPV Vaccines
Zheng, Q., He, M., Mao, Z., Huang, Y., Li, X., Long, L., Guo, M., & Zou, D. (2025) · Vaccines · doi:10.3390/vaccines13010092 · Cited by 23 · see citing works
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
Lucia, A. D., Mazzotti, L., Gaimari, A., Zurlo, M., Maltoni, R., Cerchione, C., Bravaccini, S., Delmonte, A., Crinò, L., de Souza, P. B., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1515748 · Cited by 23 · see citing works
The Future of Personalized Cancer Vaccines
Martini, D. J., & Wu, C. J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0300 · Cited by 23 · see citing works
Aptamers as target-specific recognition elements in drug delivery
Vydaline, A. O. E., Rozhkov, S., Sosa, G., & Mallikaratchy, P. R. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115685 · Cited by 23 · see citing works
Engineering STING Nanoadjuvants for spatiotemporally-tailored innate immunity stimulation and cancer vaccination therapy
Chen, F., Zhang, H., Li, S. L., Ren, S., Huang, L., Cai, Z., Yin, L., Zheng, M., Liu, X., Xu, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60927-7 · Cited by 22 · see citing works
Recent research progress and clinical status of immunotherapy for colorectal cancer
Huo, Z., Liu, G., & Li, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.089 · Cited by 23 · see citing works
Nanomaterial-assisted delivery of CpG oligodeoxynucleotides for boosting cancer immunotherapy
Zhang, Z., Yu, L., Liu, W., & Huang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.044 · Cited by 21 · see citing works
Soluble-microneedle enhance three T-cell activation signals as efficient tumor vaccines for melanoma prevention and treatment
Li, N., Mu, W., Xia, Z., Ma, Q., Feng, R., Gu, P., Yang, Q., Gao, S., Zhang, W., Wei, S., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113726 · Cited by 21 · see citing works
Cancer mRNA vaccines: clinical application progress and challenges
Li, H., Min, L., Du, H., Wei, X., & Tong, A. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217752 · Cited by 24 · see citing works
Targeting metastasis with nanomedicine
Pallares, R. M., Consolino, L., Wang, A., Lorenzi, F. D., Kiessling, F. M., Schroeder, A., & Lammers, T. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00358-7 · Cited by 25 · see citing works
Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies
Zoroddu, S., & Bagella, L. (2025) · Cells · doi:10.3390/cells14181476 · Cited by 26 · see citing works
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review
Sheikhlary, S., Lopez, D. H., Moghimi, S., & Sun, B. (2024) · Biomolecules · doi:10.3390/biom14040503 · Cited by 21 · see citing works
Intranasal and Intravenous Sequential Administration of Survivin Peptide‐CpG Nanovaccines Elicits Potent Immunity Toward Glioblastoma
Shi, Y., Sun, Y., Zhao, S., Sun, Z., Xia, M., Zhong, Z., & Meng, F. (2025) · Advanced Materials · doi:10.1002/adma.202420630 · Cited by 20 · see citing works
The role of therapeutic cancer vaccines in the modern immunotherapy era: State of the art with recent progress and future challenges
Rota, M., Torresan, I., Palmerio, S., Tasselli, E., Rossi, A., Zivi, A., & Zacchi, F. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105068 · Cited by 20 · see citing works
Programming of in Situ Tumor Vaccines via Supramolecular Nanodrug/Hydrogel Composite and Deformable Nanoadjuvant for Cancer Immunotherapy
Shao, S., Cao, Z., Xiao, Z., Yu, B., Hu, L., Du, X., & Yang, X. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02113 · Cited by 20 · see citing works
PPS-TLR7/8 agonist nanoparticles equip robust anticancer immunity by selectively prolonged activation of dendritic cells
Zhang, Y., Li, Y., Xu, L., Xu, L., Wang, Y., Li, N., Solek, N. C., Wang, Y., Li, B., & Liu, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.123032 · Cited by 19 · see citing works
Beyond Needles: Immunomodulatory Hydrogel-Guided Vaccine Delivery Systems
Rana, M. M., Demirkaya, C., & Siegler, H. D. L. H. (2024) · Gels · doi:10.3390/gels11010007 · Cited by 19 · see citing works
Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines
Li, Y., Xu, Y., Su, W., Xu, J., Ye, Z., Wang, Z., Liu, Q., & Chen, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117897 · Cited by 18 · see citing works
Potential of bacterial outer membrane vesicles in tumor vaccine: characteristics, advancements, and future directions
Yang, Y., & Wu, Y. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253004 · Cited by 18 · see citing works
Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation
Naffaa, M. M., Al-Ewaidat, O. A., Gogia, S., & Begiashvili, V. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002313 · Cited by 19 · see citing works
Biomaterials nanoplatform-based tumor vaccines for immunotherapy
Li, Z., Zhang, H., Gong, Q., & Luo, K. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.06.038 · Cited by 18 · see citing works
Metal-organic frameworks activate the cGAS-STING pathway for cancer immunotherapy
Zhu, S., Xu, W., Li, H., Sun, Z., Zhu, Y., Liu, W., & Chu, H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03669-4 · Cited by 19 · see citing works
Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins
Guo, N., Niu, Z., Yan, Z., Liu, W., Shi, L., Li, C., Yao, Y., & Shi, L. (2024) · Vaccines · doi:10.3390/vaccines12040392 · Cited by 18 · see citing works
Strategies to Overcome Hurdles in Cancer Immunotherapy
Kim, J. H., Lee, B. J., Moon, S., Lee, H., Lee, J., Kim, B., Jung, K., Seo, H., & Chung, Y. (2024) · Biomaterials Research · doi:10.34133/bmr.0080 · Cited by 19 · see citing works
Neoantigen sequestrated autophagosomes as therapeutic cancer vaccines
Zhang, J., Cao, J., Wang, L., Li, S., Meng, F., Liang, X., Jiang, H., Luo, R., Zhu, D., Zhang, F., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.019 · Cited by 18 · see citing works
The role of telomere and telomerase in cancer and novel therapeutic target: narrative review
Baylie, T., Jemal, M., Baye, G., Getinet, M., Amare, G. A., Adugna, A., Abebaw, D., Teffera, Z. H., Tegegne, B. A., Gugsa, E., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1542930 · Cited by 17 · see citing works
Strategies to Design and Optimize Artificial Antigen‐Presenting Cells for T Cell Expansion in Cancer Immunotherapy
Tuyết, N. T., & Youn, Y. S. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202426047 · Cited by 17 · see citing works
Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy
Wang, Z., Gu, Y., Sun, X., & Huang, H. (2025) · Biomarker Research · doi:10.1186/s40364-025-00808-9 · Cited by 17 · see citing works
Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy
Li, X., Kaboli, P. J., Roozitalab, G., Salahi, S., Qian, H., Zhang, X., Chen, K., & İmani, S. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01199-1 · Cited by 19 · see citing works
Physicochemical Cues Steering Spiky Mn/MoOx Nanocarriers to Mimic Oncolytic Virus for Potentiating Cancer Immunotherapy
Zhao, L., Zhao, X., Zhang, W., Miao, Y., Wang, X., & Deng, D. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202404789 · Cited by 17 · see citing works
Dynamic Size‐Change Nanovaccine for Enhancing Lymph Node Deep Penetration and Eliciting Robust Antitumor Immune Responses
Liu, L., Huang, Z., Zhu, Z., Sun, A., Zhao, J., Xu, Y., Song, W., Tang, Z., & Chen, X. (2025) · Advanced Materials · doi:10.1002/adma.202504909 · Cited by 16 · see citing works
Self-citation
Progress in cancer vaccines enabled by nanotechnology
Kim, B., Abdelfattah, N. S., Hostetler, A., & Irvine, D. J. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02021-z · Cited by 21 · see citing works
Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond
Andersen, M. H. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02710-8 · Cited by 16 · see citing works
Antigen self-presenting dendrosomes swallowing nanovaccines boost antigens and STING agonists codelivery for cancer immunotherapy
Xia, J., Chen, X., Dong, M., Liu, S., Zhang, L., Pan, J., & Wang, J. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122998 · Cited by 18 · see citing works
Telomerase-based vaccines: a promising frontier in cancer immunotherapy
Vahidi, S., & Touchaei, A. Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03624-7 · Cited by 16 · see citing works
Bifunctional Phage Particles Augment CD40 Activation and Enhance Lymph Node-Targeted Delivery of Personalized Neoantigen Vaccines
Chen, X., Lei, L., Yan, J., Wang, X., Li, L., Liu, Q., Wang, Y., Chen, T., Shao, J., Yu, L., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c14513 · Cited by 16 · see citing works
Targeting PI3K Signaling to Overcome Tumor Immunosuppression: Synergistic Strategies to Enhance Cancer Vaccine Efficacy
Cui, R., Luo, Z., Zhang, X., Yu, X., Yuan, G., Li, X., Xie, F., & Jiang, O. (2025) · Vaccines · doi:10.3390/vaccines13030292 · Cited by 16 · see citing works
Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells
Singer, M., Valerin, J. B., Zhang, Z., Zhang, Z., Dayyani, F., Yaghmai, V., Choi, A., Imagawa, D. K., & Abi‐Jaoudeh, N. (2025) · Cells · doi:10.3390/cells14030166 · Cited by 16 · see citing works
Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines
Hushmandi, K., Fooladi, A. A. I., Reiter, R. J., Farahani, N., Liang, L., Aref, A. R., Nabavi, N., Alimohammadi, M., Liu, L., & Sethi, G. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00662-3 · Cited by 16 · see citing works
Advances and challenges in cancer immunotherapy: mechanisms, clinical applications, and future directions
Vatsavai, N., Bhinder, S. K., Shaik, R., Mahira, S., Kapoor, S. S., Ali, M. S., Verma, D., Singh, J., Gari, S. B. V., Upadhyay, P., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1602529 · Cited by 15 · see citing works
Cancer vaccines: Discovery, development, and challenges for clinical translation
Zhang, Z., Yao, S., Wang, Y., Luo, K., Amiji, M. M., & Anderson, K. C. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123615 · Cited by 15 · see citing works
An Activatable and Covalent Tumor-Associated Antigen Capturer Enabling Systemic Injection In Vivo for Promoted Antitumor Immunity
Gao, Z., Miao, Z., Jia, S., Zhang, D., Zhang, H., Tian, J., Zhao, J., Xin, J., & Ding, D. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c09791 · Cited by 15 · see citing works
mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics
Dalabehera, M., Ghosh, A., Mohanty, S., Chellappan, D. K., Chaudhari, S., Ale, Y., Poonia, N., Subudhi, R. N., Khanna, M., & Lim, H. G. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102584 · Cited by 20 · see citing works
The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials
Tapescu, I., Madsen, P. J., Lowenstein, P. R., Castro, M. G., Bagley, S. J., Fan, Y., & Brem, S. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1454370 · Cited by 16 · see citing works
Revolutionizing cancer treatment: the rise of personalized immunotherapies
Fayyaz, A., Haqqi, A., Khan, R., Irfan, M., Khan, K., Reiner, Ž., Sharifi‐Rad, J., & Călina, D. C. (2024) · Discover Oncology · doi:10.1007/s12672-024-01638-1 · Cited by 16 · see citing works
Novel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence to Improve Prognoses
Kedar, P., Bhattacharya, S., Kanugo, A., & Prajapati, B. G. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673347323241119184648 · Cited by 15 · see citing works
An in-depth review of AI-powered advancements in cancer drug discovery
Le, M. H. N., Nguyen, P. K., Nguyen, T. P. T., Nguyen, H. Q., Tam, D. N. H., Huynh, H. H., Huynh, P. K., & Le, N. Q. K. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167680 · Cited by 15 · see citing works
mRNA vaccines as cancer therapies
Huang, S., Que, H., Wang, M., & Wei, X. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003455 · Cited by 14 · see citing works

Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy
Eskandari, A., Leow, T. C., Rahman, M. B. A., & Oslan, S. N. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01144-3 · Cited by 7 · see citing works
Eliciting antitumor immunity via therapeutic cancer vaccines
Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 89 · see citing works
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271 · see citing works
Cancer vaccines as targeted therapies: translational advances and challenges
Shafaghat, Z., Sadri, M., Roozbehani, M., Kheiri, F., Dorfaki, M., & Faraji, F. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2728542
Therapeutic Cancer Vaccines: Classification, Mechanisms, Challenges and Future Perspectives
Gao, J., Sun, Y., Han, Z., Zhang, H., Sun, M., Liu, S., & Zhang, B. (2026) · Immunological Investigations · doi:10.1080/08820139.2026.2733761

Authors: Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C.
Affiliations: Tongji University (CN)
Shanghai East Hospital (CN)
Corresponding author: Cao, Wanlu
Dong, Chunyan
ORCID: Fan, Ting
Zhang, Mingna
Yang, Jingxian
Zhu, Zhounan
Dong, Chunyan
Venue: Signal Transduction and Targeted Therapy
Publisher: Springer Science and Business Media LLC
Published: 2023-12-13
Volume: 8
Issue: 1
Pages: 450-450
ISSN: 2059-3635 (ISSN-L)
DOI: 10.1038/s41392-023-01674-3
PMC: PMC10716479
OpenAlex: W4389639889
Cited by: 597
References: 235
Citations by year: 2026: 187 · 2025: 292 · 2024: 116 · 2023: 2
FWCI: 16.60
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Natural Science Foundation of China (81573008, 81860547, 82203861)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: therapeutic cancer vaccines, cancer immunotherapy, tumor-associated antigens, tumor-specific antigens, antigen delivery systems, antigen presentation, tumor immune microenvironment, vaccine production, clinical trials, antitumor efficacy, T cell response
MeSH terms: Antigens, Neoplasm, Humans, Immunity, Immunotherapy, Neoplasms, Cancer Vaccines, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic cancer vaccines: Advancements, challenges, and prospects

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks